COMPANY

Abcuro

HQ: Newton, MA source · abcuro.com ↗ · New England

Keywords: immunology autoimmune diseases inclusion body myositis melanoma T-cell Large Granular Lymphocytic Leukemia ABC008 Ulviprubart (ABC008)

Location: Newton, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series D · $66M · announced Aug 18, 2026 Company release ↗
Source quote
- Aug 18, 2026 · Company release ↗
  “– Abcuro … Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participatio”
Raise Series C · $200M · announced Feb 12, 2025 Company release ↗
Source quote
- Feb 12, 2025 · Company release ↗
  “– Abcuro … Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the closing of a $200 million Series C financing led by New Enterprise Associates (NEA) with Foresite Ca”

Raises announced in these releases: $266M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Aug 18, 2026 Raise Private equity round — Series D: $66M (total, as published), announced Aug 18, 2026. Source: company's own press page. source ↗ · Form D filed Aug 13, 2026 SEC Form D ↗
Aug 18, 2026 Raise Series D · $66M source ↗
Feb 12, 2025 Raise Private equity round — Series C: $200M (total, as published), announced Feb 12, 2025. Source: company's own press page. source ↗
Feb 12, 2025 Raise Series C · $200M source ↗
Oct 21, 2024 Trial start Phase 2/Phase 3: Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis source ↗
Feb 28, 2023 Trial start Phase 2/Phase 3: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis source ↗
Sep 28, 2022 Trial start Phase 1/Phase 2: ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) source ↗
May 25, 2021 Trial start 1: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) source ↗

2029-01 (ESTIMATED) · Phase 2/Phase 3 · Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis · NCT06450886

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $266.0M. Last 2 years.

Aug 18, 2026 Private equity round — Series D: $66M (total, as published), announced Aug 18, 2026. Source: company's own press page. source ↗ · Form D filed Aug 13, 2026 SEC Form D ↗
Feb 12, 2025 Private equity round — Series C: $200M (total, as published), announced Feb 12, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05721573	A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis	Phase 2/Phase 3	Completed	Feb 28, 2023	Nov 6, 2025 (actual)
NCT05532722	ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)	Phase 1/Phase 2	Completed	Sep 28, 2022	Aug 28, 2025 (actual)
NCT06450886	Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis	Phase 2/Phase 3	Active, not recruiting	Oct 21, 2024	2029-01 (estimated)
NCT04659031	A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)	1	Completed	May 25, 2021	Jan 10, 2025 (actual)

Annual award amounts. Total $295K.

Jul 27, 2020 NIH award 5R43CA243728-02 FY2020: $37,385 awarded for that fiscal year; activity R43 (SBIR); PI GULLA, STEFANO; recipient as written: ABCURO, INC., Newton, MA. Antibody blockade of T cell activating co-inhibitory rec source ↗
Aug 20, 2019 NIH award 1R43CA243728-01 FY2019: $257,932 awarded for that fiscal year; activity R43 (SBIR); PI GULLA, STEFANO; recipient as written: ABCURO, INC., Newton, MA. Antibody blockade of T cell activating co-inhibitory re source ↗